Latest On Idorsia Ltd (IDRSF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-01 05:13 EST | News | Idorsia: Disappointing Detour On The Road To Revenue (Rating Downgrade) | N/A |  |
| 2023-04-27 01:13 EST | News | Idorsia GAAP EPS of -CHF1.19, revenue of CHF21M | N/A | |
| 2023-04-26 13:09 EST | News | Idorsia: A Trough Year, But Long-Term Potential | N/A | |
| 2023-04-26 00:49 EST | News | Idorsia Ltd (IDRSF) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-25 12:52 EST | News | Idorsia Ltd 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-02-08 16:34 EST | News | Idorsia Is Now A Buy | N/A | |
| 2023-02-08 16:34 EST | News | Idorsia: The Market Has Overreacted | N/A | |
| 2023-02-08 03:08 EST | News | Idorsia Ltd (IDRSF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-07 14:20 EST | News | Idorsia GAAP EPS of -CHF4.67, revenue of CHF97M | N/A | |
| 2023-02-04 17:32 EST | News | Idorsia: Interesting Swiss Biotech, But Commercialization Seems Uncertain | N/A | |
| 2023-01-03 10:33 EST | News | Idorsia: The Foundation Is In Place And The Co. Is Ready For Great Success In 2023 | N/A | |
| 2022-11-11 22:20 EST | News | Idorsia: It's Time To Be Greedy (Technical Analysis) | N/A | |
| 2022-11-10 10:14 EST | News | Idorsia (IDRSF) Investor Presentation - Slideshow | N/A | |
| 2022-10-29 01:08 EST | News | Idorsia Ltd (IDSRF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-10-25 20:29 EST | News | Idorsia Non-GAAP EPS of -CHF1.22, revenue of CHF21M misses by CHF6.65M | N/A | |
| 2022-08-24 14:22 EST | News | Idorsia: Someone Is Playing With Fire | N/A | |
| 2022-07-27 00:40 EST | News | Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-26 11:08 EST | News | Idorsia GAAP EPS of -CHF1.25, revenue of CHF17M | N/A | |
| 2022-07-26 11:08 EST | News | Idorsia Ltd 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-07-22 09:34 EST | News | Idorsia: Q2 Results Should Reveal Marketing Success For Newly Approved FDA Drug | N/A | |
| 2022-05-27 13:56 EST | News | Idorsia Is Likely Set For A Short Squeeze | N/A | |
| 2022-03-18 07:18 EST | News | Idorsia: Positive Catalyst Coming Very Soon | N/A | |
| 2022-02-09 05:08 EST | News | Idorsia Ltd 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-09 05:08 EST | News | Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-08 10:34 EST | News | Idorsia GAAP EPS of -CHF 1.32, revenue of CHF 5M | N/A | |
| 2022-01-21 20:54 EST | News | Idorsia: Heading Towards Profitability Faster Than Expected | N/A | |
| 2021-12-30 23:01 EST | News | Idorsia: FDA Decision By January 8, 2022 | N/A | |
| 2021-10-11 22:28 EST | News | Idorsia phase 3 Fabry disease candidate lucerastat misses primary endpoint | N/A | |
| 2021-09-07 05:52 EST | News | Idorsia: The Clock Is Ticking For The Countdown | N/A | |
| 2021-08-02 09:23 EST | News | Idorsia reports 1H results | N/A | |
| 2021-07-29 10:41 EST | News | Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-27 21:23 EST | News | Idorsia Ltd 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-22 14:28 EST | News | Idorsia: Putting The Capstone On A Foundationally Strong Biotech | N/A | |
| 2021-04-22 06:28 EST | News | Idorsia reports Q1 results | N/A | |
| 2021-03-12 17:11 EST | News | FDA accepts Idorsia's daridorexant new drug application for review | N/A | |
| 2021-02-15 09:23 EST | News | Idorsia: Reaching Out For More And Grabbing The Gold Ring For Investors | N/A | |
| 2021-02-10 09:27 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-05 19:44 EST | News | Idorsia Ltd (IDRSF) CEO Jean-Paul Clozel on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-05 01:51 EST | News | Idorsia reports Q4 results | N/A | |
| 2021-01-21 03:36 EST | News | Idorsia (IDRSF) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow | N/A | |
| 2020-11-26 23:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-03 10:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 12:33 EST | News | Idorsia: Reaching Out For More And Delivering On Their Promises | N/A | |
| 2020-11-02 11:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:21 EST | Financials | Company financials have been released. | Neutral | |
About Idorsia Ltd (IDRSF):
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
General
- Name Idorsia Ltd
- Symbol IDRSF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- Web URLhttp://www.idorsia.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 52.63
- Price/Book (Most Recent Quarter) 7.52
- Enterprise Value Revenue 60.83
View More
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -21%
- Return on Equity -119%
- Earnings Per Share -$1.77
- Revenue Per Share $0
- Gross Profit -309318000
- Quarterly Earnings Growth 40.5%
View More
Highlights
- Market Capitalization 4.77 billion
- Book Value Per Share $5.98
View More
Share Statistics
- Shares Outstanding 166.45 million
- Shares Float 108.71 million
- % Held by Insiders 2925%
- % Held by Institutions 20.97%
View More
Technicals
- Beta 0.75
- 52 Week High $33.83
- 52 Week Low $24.13
- 50 Day Moving Average 28.53
- 200 Day Moving Average 28.39
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Idorsia Ltd (IDRSF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Idorsia Ltd (IDRSF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $5.82 million | -$0.94 | ||
| 2020-09-30 | 2020-12-31 | $7.77 million | -$0.96 | -$0.85 | -13.12% |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.91 | -$0.82 | -10.46% |
| 2020-03-31 | 2020-06-30 | $5.02 million | -$0.54 | -$0.86 | 37.64% |
| 2019-12-31 | 2020-03-31 | $4.15 million | -$0.95 | -$1.00 | 4.97% |
| 2019-09-30 | 2019-12-31 | $6.56 million | -$1.12 | -$1.09 | -2.41% |
| 2019-06-30 | 2019-09-30 | $6.56 million | -$0.92 | -$0.99 | 7.53% |
| 2019-03-31 | 2019-06-30 | $6.56 million | -$0.98 | -$0.99 | 0.68% |
| 2018-12-31 | 2019-03-31 | $40.94 million | -$0.82 | ||
| 2018-09-30 | 2018-12-31 | $6.56 million | -$0.84 | -$0.79 | -6.43% |
| 2018-06-30 | 2018-09-30 | $8.62 million | -$0.94 | -$0.80 | -16.94% |
| 2018-03-31 | 2018-06-30 | $6.56 million | -$0.69 | -$0.80 | 14.18% |
| 2017-12-31 | 2018-03-31 | $256.15 million | -$0.69 | -$0.80 | 13.54% |
| 2017-09-30 | 2017-12-31 | $N/A | $0.54 | ||
| 2017-06-30 | 2017-09-30 | $N/A | -$0.61 | -$0.80 | 23.24% |
| 2017-03-31 | 2017-06-30 | $N/A | $1.15 | $0.00 | |
| 2016-12-31 | 2017-03-31 | -$0.96 | $0.00 |
Idorsia Ltd (IDRSF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 91.49 million | 92.91 million | N/A | 96.77 million | N/A |
| Income Before Tax | -141.52 million | -119.43 million | N/A | -118.82 million | -136.11 million |
| Selling General Administrative | 35 million | 15.96 million | N/A | 18.95 million | 17.91 million |
| Gross Profit | N/A | N/A | N/A | N/A | -107.54 million |
| Ebit | -134.46 million | -112.37 million | N/A | -111.69 million | -125.77 million |
| Operating Income | -123.95 million | -110.39 million | N/A | -111.01 million | -125.77 million |
| Income Tax Expense | -4.56 million | N/A | -117000 | N/A | 5.94 million |
| Total Revenue | 5.82 million | 7.77 million | N/A | 5.02 million | 4.15 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 111.69 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -10.34 million |
| Net Income From Continuing Operations | -136.96 million | -118.48 million | N/A | -120.29 million | -142.05 million |
| Net Income Applicable to Common Shares | -136.96 million | N/A | -69.32 million | N/A | -141.76 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -145.86 million | N/A | -62.29 million | 9.99 million | 10.48 million |
| Change to Liabilities | N/A | -550000 | N/A | -4.17 million | -6.14 million |
| Total Cash Flow from Investing Activities | N/A | 5.51 million | N/A | 4.33 million | 42.59 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | 22.62 million | N/A | 5.04 million | 663000 |
| Change in Cash | -232.7 million | N/A | -168.25 million | -121.99 million | -81.77 million |
| Total Cash from Operating Activities | -91.6 million | -43.74 million | N/A | -126.17 million | -124.44 million |
| Depreciation | 4.66 million | N/A | 4.87 million | 5.05 million | 4.89 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | -1000 | 39.36 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 431000 | -8.3 million |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | 325000 | N/A | 7.17 million | 2.27 million |
| Capital Expenditures | 1.83 million | N/A | 1.97 million | 5.51 million | 7.25 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 849.88 million | 838.89 million | N/A | 832.17 million | 839.85 million |
| Total Stockholder Equity | 585.48 million | 210 million | N/A | 57.93 million | 172.44 million |
| Other Current Liabilities | 19.16 million | 2000 | N/A | 1000 | 19.09 million |
| Total Assets | 1.44 billion | 1.05 billion | N/A | 881.75 million | 1 billion |
| Common Stock | 8.32 million | N/A | 7.12 million | N/A | 6.56 million |
| Other Current Assets | 7.14 million | 15.74 million | N/A | 25.03 million | 8.69 million |
| Retained Earnings | -1.35 billion | -1.21 billion | -1.09 billion | -1.01 billion | -894.27 million |
| Other Liabilities | 91.95 million | N/A | 83.53 million | N/A | 106.39 million |
| Other Assets | 201.08 million | N/A | 189.02 million | N/A | 8.98 million |
| Cash | 140.81 million | 148.21 million | N/A | 94.76 million | 263.01 million |
| Total Current Liabilities | 127.47 million | 128.72 million | N/A | 113.21 million | 110.88 million |
| Other Stockholder Equity | -38.1 million | N/A | -23.78 million | N/A | -23.53 million |
| Property, Plant & Equipment | 196.22 million | N/A | 198.39 million | N/A | 206.73 million |
| Total Current Assets | 1.03 billion | 838.23 million | N/A | 480.99 million | 775.4 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 11.4 million |
| Net Tangible Assets | 584.9 million | N/A | 319.17 million | N/A | 170.75 million |
| Short Term Investments | 869.22 million | N/A | N/A | N/A | 480.06 million |
| Long Term Debt | 587.35 million | 585.24 million | N/A | 581.06 million | 579 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 11.12 million | 11.99 million | N/A | 8.98 million | 8.76 million |
Idorsia Ltd (IDRSF) Chart:
Idorsia Ltd (IDRSF) News:
Below you will find a list of latest news for Idorsia Ltd (IDRSF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Idorsia Ltd (IDRSF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Idorsia Ltd (IDRSF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|